Lily Ting
Senior Director, External Research & Innovation Lundbeck
Seminars
Thursday 23rd July 2026
Fireside Chat: Big Pharma Perspective on Emerging Commercial Opportunity to Investigate Existing Autoimmune Therapeutics within the Myasthenia Gravis & Peripheral Neuropathies Space
3:00 pm
- Evaluating MG as a high-growth yet increasingly oversaturated market, recognising that multiple FcRn and C5 inhibitors show comparable aggregate efficacy but compete for a finite rare-disease population
- Identifying CIDP and MMN as commercially compelling but biologically underdefined opportunities, due to uncertainty around immunologic origin, incomplete real-world efficacy and unclear prevalence
- Balancing chronic suppression models against emerging immune-reset approaches, comparing repeated FcRn/complement administration with upstream
- B-cell or CAR-T interventions to inform long-term investment decisions focused on durable remission and defensible market positioning
